- Home
- DX vs HRMY Comparison
DX vs HRMY Comparison
Compare DX & HRMY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | DX | HRMY |
|---|---|---|
| Founded | 1987 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0B | 2.2B |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | DX | HRMY |
|---|---|---|
| Price | $14.63 | $36.23 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 8 |
| Target Price | $13.83 | ★ $49.75 |
| AVG Volume (30 Days) | ★ 5.9M | 642.2K |
| Earning Date | 01-27-2026 | 02-24-2026 |
| Dividend Yield | ★ 14.31% | N/A |
| EPS Growth | 35.65 | ★ 50.44 |
| EPS | 1.66 | ★ 3.17 |
| Revenue | $230,447,000.00 | ★ $825,944,000.00 |
| Revenue This Year | N/A | $23.29 |
| Revenue Next Year | $134.14 | $15.98 |
| P/E Ratio | ★ $8.59 | $11.49 |
| Revenue Growth | ★ 87.09 | 21.13 |
| 52 Week Low | $10.79 | $25.52 |
| 52 Week High | $14.52 | $40.93 |
Technical Indicators
Market Signals| Indicator | DX | HRMY |
|---|---|---|
| Relative Strength Index (RSI) | 76.15 | 44.31 |
| Support Level | $13.90 | $34.68 |
| Resistance Level | $14.13 | $39.40 |
| Average True Range (ATR) | 0.23 | 1.32 |
| MACD | 0.04 | -0.33 |
| Stochastic Oscillator | 99.45 | 32.84 |
Price Performance
Historical ComparisonAbout DX Dynex Capital Inc.
Dynex Capital Inc is an internally managed mortgage real estate investment trust, which invests in mortgage-backed securities. The company invests in residential and commercial mortgage-backed securities. Its objective is to provide attractive risk-adjusted returns to shareholders over the long term that are reflective of a leveraged, high quality fixed income portfolio with a focus on capital preservation. Its investments consist principally of Agency mortgage-backed securities including, residential MBS and commercial MBS.
About HRMY Harmony Biosciences Holdings Inc.
Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company's product WAKIX (pitolisant) is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and is used for the treatment of cataplexy in adult patients with narcolepsy. The other drug candidates in its pipeline are Pitolisant, HBS-102 (MCHR1 antagonist), BP1.15205 (orexin-2 receptor agonist), ZYN002 (cannabidiol gel), EPX-100 (clemizole hydrochloride), and EPX-200 (lorcaserin), among others.